Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Paradigm Biopharmaceuticals ( (AU:PAR) ) has provided an announcement.
Paradigm Biopharmaceuticals Limited announced the issuance of 7,000,000 unquoted convertible notes as part of a previously disclosed transaction. This move is part of the company’s strategic financial maneuvers to support its ongoing development projects, potentially strengthening its position in the pharmaceutical industry and impacting stakeholders by enhancing its operational capabilities.
The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.80 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Limited operates in the pharmaceutical industry, focusing on developing and commercializing therapies for rare and debilitating diseases. The company is known for its work in advancing treatments that address unmet medical needs, particularly in the area of musculoskeletal disorders.
YTD Price Performance: 24.00%
Average Trading Volume: 922,981
Technical Sentiment Signal: Buy
Current Market Cap: A$184.8M
For an in-depth examination of PAR stock, go to TipRanks’ Overview page.